Merit Medical Systems, Inc. (MMSI)
Here's Why You Should Add Merit Medical Stock to Your Portfolio Now
MMSI's WRAPSODY reimbursement tailwinds, expanding high-margin portfolio and strong cash flow set up growth into 2026 despite macro and forex headwinds.
Why Merit Medical (MMSI) is Poised to Beat Earnings Estimates Again
Merit Medical (MMSI) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Merit Medical Systems, Inc. (MMSI) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Merit Medical Systems, Inc. (MMSI) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Here's Why You Should Retain Merit Medical Stock in Your Portfolio Now
Merit Medical shows resilience despite 2025 share pressure, supported by cardiovascular growth, margin expansion and WRAPSODY CIE momentum.
Why Merit Medical (MMSI) is a Top Momentum Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Merit Medical (MMSI) Upgraded to Buy: What Does It Mean for the Stock?
Merit Medical (MMSI) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Merit Medical Q3 Earnings & Revenues Beat Estimate, Margins Expand
MMSI beats third-quarter 2025 estimates on strong revenue and margin growth, prompting a raised full-year outlook across segments.
Merit Medical Systems, Inc. (MMSI) Q3 2025 Earnings Call Transcript
Merit Medical Systems, Inc. ( MMSI ) Q3 2025 Earnings Call October 30, 2025 5:00 PM EDT Company Participants Martha Aronson - President, CEO & Director Brian Lloyd - Chief Legal Officer & Corporate Secretary Raul Parra - CFO & Treasurer Conference Call Participants Jason Bednar - Piper Sandler & Co., Research Division Lilia-Celine Lozada - JPMorgan Chase & Co, Research Division Jayson Bedford - Raymond James & Associates, Inc., Research Division Michael Matson - Needham & Company, LLC, Research Division John Young - Canaccord Genuity Corp., Research Division David Rescott - Robert W. Baird & Co. Incorporated, Research Division Michael Petusky - Barrington Research Associates, Inc., Research Division James Sidoti - Sidoti & Company, LLC Presentation Operator Thank you for standing by, and welcome to the Merit Medical Systems Third Quarter 2025 Earnings Conference Call.
Merit Medical (MMSI) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
While the top- and bottom-line numbers for Merit Medical (MMSI) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Merit Medical (MMSI) Q3 Earnings and Revenues Surpass Estimates
Merit Medical (MMSI) came out with quarterly earnings of $0.92 per share, beating the Zacks Consensus Estimate of $0.82 per share. This compares to earnings of $0.86 per share a year ago.
MMSI or SAUHY: Which Is the Better Value Stock Right Now?
Investors looking for stocks in the Medical - Dental Supplies sector might want to consider either Merit Medical (MMSI) or Straumann Holding AG (SAUHY). But which of these two companies is the best option for those looking for undervalued stocks?
Merit Medical Expands GI Portfolio With $22M C2 CryoBalloon Acquisition
MMSI is set to acquire C2 CryoBalloon from Pentax for $22M, strengthening its GI portfolio. Despite near-term dilution, the deal positions Merit for long-term growth in gastroenterology.
